DW4421
Phase 1Small molecule
Daewon Pharmaceutical Co., Ltd.DW4421 is one of 84 small molecule programs targeting Interaction. It is currently in Phase 1.
2
Indications
4
Total Trials
3
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
127 competitors in Clinical Trial
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Venclexta
AbbViePhase 3
Avelox
BayerPhase 3
Paraplatin
AAvyxa
Phase 3
Opzelura
DDizal Pharmaceuticals
Phase 3
Potassium Iodide
MMeda Pharmaceuticals
Phase 3
Ablysinol
CSL BehringPhase 3
Nascobal
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
MCV4
CanSino Biologics Inc.Phase 3
Buagafuran
BBeijing Union Pharmaceutical Factory Ltd
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Clinical Trial2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DW4421. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details